Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Receivables (2021 - 2025)

Senti Biosciences has reported Receivables over the past 5 years, most recently at $500000.0 for Q4 2025.

  • For Q4 2025, Receivables fell 28.57% year-over-year to $500000.0; the TTM value through Dec 2025 reached $500000.0, down 28.57%, while the annual FY2025 figure was $500000.0, 28.57% down from the prior year.
  • Receivables for Q4 2025 was $500000.0 at Senti Biosciences, down from $1.0 million in the prior quarter.
  • Over five years, Receivables peaked at $17.6 million in Q4 2023 and troughed at $168000.0 in Q2 2025.
  • A 5-year average of $1.9 million and a median of $846000.0 in 2022 define the central range for Receivables.
  • Biggest five-year swings in Receivables: plummeted 96.02% in 2024 and later surged 132.33% in 2025.
  • Year by year, Receivables stood at $483000.0 in 2021, then surged by 75.16% to $846000.0 in 2022, then surged by 1979.43% to $17.6 million in 2023, then plummeted by 96.02% to $700000.0 in 2024, then dropped by 28.57% to $500000.0 in 2025.
  • Business Quant data shows Receivables for SNTI at $500000.0 in Q4 2025, $1.0 million in Q3 2025, and $168000.0 in Q2 2025.